Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.42 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 11/20 | 0.35 |
| ▸ | HTR2A | P28223 | 11/20 | 0.35 |
| ▸ | DRD3 | P35462 | 11/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17894548 | 1.00 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL17899786 | 1.00 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL17894547 | 1.00 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6679812 | 0.82 | KDM4E (0.38) | SLC9A1DRD2 | |
| SCHEMBL6679801 | 0.82 | KDM4E (0.38) | SLC9A1DRD2 | |
| SCHEMBL6679807 | 0.82 | KDM4E (0.38) | SLC9A1DRD2 | |
| SCHEMBL6682308 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL6678123 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL19699401 | 0.81 | SLC9A1 (0.52) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 | |
| SCHEMBL19699403 | 0.75 | MTNR1B (0.64) | SLC9A1MTNR1BSLC9A5SLC9A2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | TRMT1, SULT1A1, TMT1A | SLC9A1 2520/4885MTNR1B 1442/4885SLC9A5 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.